ArticleNeurochemical research2026
Esketamine Alleviates Postoperative Cognitive Dysfunction via Rock2/Add1 Signaling Pathway in Aged Mice.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Postoperative cognitive dysfunction (POCD) is common in elderly surgical patients, and it can prolong recovery time and affect the quality of life. Although esketamine has been reported to alleviate POCD, its specific mechanism is not yet fully understood. This study investigates the effects of esketamine on POCD and its underlying molecular mechanisms. After exploratory laparotomy under isoflurane anesthesia, aged mice were treated with 10 mg/kg of esketamine via intraperitoneal injection. The findings of this study indicate that intraperitoneal administration of esketamine could alleviate POCD, as demonstrated through a suite of behavioral tests. Moreover, we collected hippocampal samples and used proteomics to obtain differentially expressed proteins, then cross-referenced them with the GO database to identify Rho-associated coiled-coil kinase 2 (Rock2) as a potential target molecule for esketamine to alleviate POCD. We further confirmed using Western blotting that esketamine downregulates the increase in Rock2 expression and the phosphorylation of the Ser726 site on alpha-adducin (S726-Add1) induced by anesthesia and surgery in aged mice. Furthermore, the damage to dendritic spine density, dendritic complexity, and synaptic plasticity in the hippocampal region caused by anesthesia and surgery showed improvement to a certain extent after esketamine treatment, as demonstrated by Golgi staining, transmission electron microscopy, and electrophysiological assessments. In summary, esketamine improved POCD in aged mice, indicating that its mechanism may involve the protection of synaptic plasticity through the Rock2/Add1 pathway. This research may provide new perspectives for the pharmacological treatment of POCD.
Indexed as
Identifiers
41779095What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.